Company signals · Biotech & Pharma
Novartis AG
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: The wider read — a Talent Market Index of 105.8 (Hot), down 2.4 month-on-month — shows Americas signal flow rising (+2.4pts).
Novartis AG: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies.
Signals at Novartis AG
MitchelLake in this thematic
More signals across Biotech & Pharma
Partnership · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced a partnership with Nvidia to build an advanced AI supercomputer system for drug discovery and development, positioning it as the most advanced and energy-efficient system in biopharma.
Product Launch · Americas
Boehringer Ingelheim →Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine initiated Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. infants and toddlers (3 months to under 4 years) with classic congenital adrenal hyperplasia, with concurrent EU trial at target enrollment. Moving toward supplemental U.S. filing to extend indication into pediatric population with no approved therapies.
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Intelligence powered by Autonodal ↗